Abstract
Prostate-specific membrane antigen targeting positron emission tomography (PSMA-PET) has become since recent years increasingly important in the management of patients with prostate cancer. Initially limited to the use in patients with prostate cancer biochemical recurrence in France, PSMA-PET is now routinely use in various setting in prostate cancer patients, on the one hand for initial staging in patients with high-risk prostate cancer, and in the other hands to assess the eligibility for radioligand therapy using PSMA ligands. Other studies are currently assessing PSMA-PET in other settings such as the characterization of prostate disease, the guidance of biopsies or even as a tool for therapeutic assessment in patients with metastatic cancer. The objective of this review is to describe the current use of PSMA-PET in France in 2023, and the perspective of PSMA-PET imaging in the management of patients with prostate cancer in the future.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
